Pancreatic Cancer Research

ResearcherErasmus MCActive in the last 2 years

Joost J.M.E. Nuyttens

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0002-5021-1597; OpenAlex author ID A5108229737. Sources: ClinicalTrials.gov.

Their work

Papers
25 (first author 2, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
76
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 4 papers · 2020: 2 papers · 2021: 3 papers, 1 trial · 2022: 4 papers · 2023: 4 papers · 2024: 2 papers · 2025: 2 papers · 2026: 2 papers

Papers 25

  1. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  2. The Value of Stereotactic Radiotherapy After FOLFIRINOX in Patients with Pancreatic Cancer with Vascular Contact-A Nationwide, Retrospective Cohort Study. Co-author DOI 10.3390/cancers18040700↗
  3. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  4. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  5. Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten. Letter to the Editor regarding: "Pancreat… Co-author DOI 10.1016/j.annonc.2024.05.003↗
  6. Preoperative chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula after pancreatoduodenectomy for pancrea… Co-author DOI 10.1016/j.surg.2024.01.029↗
  7. Feasibility, safety, and efficacy of stereotactic body radiotherapy combined with intradermal heat-killed mycobacterium obuense (IMM-101) vaccination for non-p… Co-author DOI 10.1016/j.radonc.2023.109541↗
  8. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderl… Co-author DOI 10.1093/bjs/znad210↗
  9. Correction: Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PAN… Co-author DOI 10.1186/s12885-023-10521-1↗
  10. Correction: A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation … Co-author DOI 10.1186/s13063-022-07036-8↗
  11. Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a na… Co-author DOI 10.1186/s12885-022-10419-4↗
  12. A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARC… Co-author DOI 10.1186/s13063-022-06829-1↗
  13. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREO… Co-author DOI 10.1200/jco.21.02233↗
  14. Immunomodulatory Effects of Stereotactic Body Radiotherapy and Vaccination with Heat-Killed Mycobacterium Obuense (IMM-101) in Patients with Locally Advanced P… Co-author DOI 10.3390/cancers14215299↗
  15. Comparison of Daily Online Plan Adaptation Strategies for a Cohort of Pancreatic Cancer Patients Treated with SBRT. Co-author DOI 10.1016/j.ijrobp.2021.03.050↗
  16. A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome. Last author DOI 10.1016/j.radonc.2020.11.006↗
  17. Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.1245/s10434-021-10276-8↗
  18. The yield of chest computed tomography in patients with locally advanced pancreatic cancer. Co-author DOI 10.1002/jso.25968↗
  19. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III P… Co-author DOI 10.1200/jco.19.02274↗
  20. Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial). First author DOI 10.1016/j.eclinm.2019.10.013↗
  21. Postoperative surveillance of pancreatic cancer patients. Co-author DOI 10.1016/j.ejso.2019.05.031↗
  22. Pancreatic cancer treated with SBRT: Effect of anatomical interfraction variations on dose to organs at risk. Last author DOI 10.1016/j.radonc.2019.01.020↗
  23. Modeling daily changes in organ-at-risk anatomy in a cohort of pancreatic cancer patients. Co-author DOI 10.1016/j.radonc.2019.01.030↗
  24. FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study. First author DOI 10.1002/jso.25233↗
  25. Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer. Co-author DOI 10.1016/j.radonc.2010.10.016↗

Trials 1

  1. Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy Principal investigator NCT04881487↗

Closest collaborators

The 25 strongest of 76 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bas Groot Koerkamp · 16 shared papers, 1 shared trial, 2018–2026 · strength 2.27
  2. Casper H.J. van Eijck · 17 shared papers, 2011–2026 · strength 2.11
  3. Marc G. Besselink · 12 shared papers, 1 shared trial, 2019–2026 · strength 1.80
  4. Johanna W. Wilmink · 12 shared papers, 2019–2026 · strength 1.56
  5. Izaak Quintus Molenaar · 8 shared papers, 1 shared trial, 2019–2026 · strength 1.36
  6. Geertjan van Tienhoven · 11 shared papers, 2011–2025 · strength 1.29
  7. Hjalmar C. van Santvoort · 9 shared papers, 2019–2026 · strength 1.26
  8. Martijn Intven · 7 shared papers, 1 shared trial, 2019–2026 · strength 1.23
  9. Anna M E Bruynzeel · 6 shared papers, 1 shared trial, 2021–2025 · strength 1.13
  10. Marjolein Y.V. Homs · 8 shared papers, 2020–2026 · strength 1.07
  11. Eva Versteijne · 7 shared papers, 2020–2025 · strength 0.93
  12. Mustafa Suker · 8 shared papers, 2018–2023 · strength 0.89
  13. Bert A. Bonsing · 7 shared papers, 2019–2025 · strength 0.86
  14. Ignace H. J. T. de Hingh · 6 shared papers, 2020–2026 · strength 0.83
  15. Sebastiaan Festen · 5 shared papers, 2020–2026 · strength 0.68
  16. Ferry A.L.M. Eskens · 6 shared papers, 2018–2022 · strength 0.65
  17. Hanneke W.M. van Laarhoven · 5 shared papers, 2019–2023 · strength 0.62
  18. Gijs A. Patijn · 5 shared papers, 2020–2025 · strength 0.62
  19. Judith de Vos‐Geelen · 5 shared papers, 2020–2025 · strength 0.62
  20. Martijn W.J. Stommel · 4 shared papers, 2019–2026 · strength 0.61
  21. Mauro Loi · 4 shared papers, 2019–2024 · strength 0.57
  22. Lois A. Daamen · 4 shared papers, 2019–2026 · strength 0.57
  23. Freek R. van ‘t Land · 3 shared papers, 2022–2026 · strength 0.51
  24. Vincent Erwin de Meijer · 3 shared papers, 2023–2026 · strength 0.50
  25. Jacob L. van Dam · 4 shared papers, 2021–2025 · strength 0.50

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.